Clyde Biosciences presenting a talk and poster at the Safety Pharmacology Society Annual meeting

Professor Godfrey Smith, Chief Scientific Officer at Clyde Biosciences will be presenting both a talk and a poster at the Safety Pharmacology Society’s Annual Conference in Utrecht, Netherlands (13–15 October 2025). His presentation will highlight Clyde's collaborative work with major pharmaceutical companies, regulatory agencies, and hiPSC cardiomyocyte providers to develop and validate new approach methodologies (NAMs) for cardiovascular safety assessment.  

His talk titled "Innovative Approaches in Preclinical Cardiac Drug Development - NAMs, Organoids and Beyond." will demonstrate how hiPSC cardiomyocytes can accurately assess acute and chronic actions of a drug. Utilising the CellOPTIQ platform, we can identify a plethora of cardiac safety issues with excellent accuracy. Further, using 2D and 3D formats, we are able to run prolonged exposures up to two weeks in duration.

His poster titled "A study of the reliability of the electrophysiological effects of dofetilide on commercial hiSPC-cardiomyocytes" focuses on the validation of the CiPA Myocyte Assay through working with the FDA and large pharmas. Data will be presented on the effect of dofetilide over a decade of studies. The data demonstrates the reliability of hiPSC cardiomyocytes on Clyde's CellOPTIQ platform.